The cardiovascular and neurological benefits of slow breathing with prolonged exhalation have been known for centuries
RESPeRATE patented technology delivers these known benefits via a smart portable device with unprecedented efficacy to significantly lower blood pressure and induces sleep.
RESPeRATE was clinically demonstrated to lower neural sympathetic activity [3,4,20,33], treat hypertension [2,5-21], heart-failure [4,22-24, 32], COPD , PSTD [26, 33], reduce, chronic stress  and anxiety  and more.
RESPeRATE is now recommended by the American Heart Association Scientific statement on non-pharmacological treatments for hypertension. 
The award-winning 2breathe Sleep Inducer was developed after finding that 90% of RESPeRATE users surveyed reported they also slept better
The overall evidence from clinical trials and meta-analyses suggests that device-guided slow breathing [RESPeRATE] can significantly lower blood pressure. There are no known contraindications to the use of the device, and no adverse effects have been noted.”American Heart Association Scientific Statement 2013. 
RESPeRATE safety and efficacy were demonstrated in 17 separate clinical studies published in peer-reviewed medical journals. It has been used by over 250,000 patients and doctors in the past 15 years with great success and no reports of adverse reactions.
The clinical studies demonstrated that using RESPeRATE as directed resulted in:
• Significant and sustained reduction in blood pressure (BP) within 8 weeks demonstrated when measured at the office [2-18], at home [3-7, 9, 12-13, 17] and with 24-hour ABPM [4,10, 19].
• 10/5 mmHg (weighted average) sustained office BP reduction in adults both with controlled and uncontrolled BP (weighted average from the 16 studies (chart 1) [2-18]. Patients population ranged from controlled patients to refractory hypertensives , included comorbidities as diabetes [9, 11, 17, 19,] and obstructive sleep apnea , in the US, Europe, Middle East, and the Far East.
• Data available from 10 studies [2-8,10-11] show greater BP reductions for:
• Older patients: 16/7 mmHg for >age 65
• Higher initial BP: 17/7 for systolic BP>160 mmHg
• More time spent in slow breathing (<10 breaths/min) [chart 3].
• BP reductions were independent of gender and medications
RESPeRATE’s patented “Device-Guided Breathing” taps the body’s natural tendency to follow musical rhythms. RESPeRATE analyses the breathing pattern and composes, in real time, a personalized melody with two distinct inhale and exhale guiding tones. By gradually prolonging the exhalation tone RESPeRATE leads the patient to the therapeutic zone of 5-6 breaths per minutes with prolonged exhalation guiding tones.
After each session of device-guided breathing, respiration returns to normal, but the beneficial impact on blood pressure accumulates and maintained with routine use.